WHO halts Hydroxychloroquine clinical trial over safety concerns
Category: #health  By Pankaj Singh  Date: 2020-05-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

WHO halts Hydroxychloroquine clinical trial over safety concerns

The malaria drug Hydroxychloroquine has been in the headlines for the past few months. The drug was hailed as the game-changer in the treatment of COVID-19 by the Trump administration. However, the WHO (World Health Organization) has reportedly halted the ongoing clinical trial of the malaria drug for potential COVID-19 treatment due to concerns about its lethal side effects.

Sources cite that the agency’s decision was based on a new study published in The Lancet on the previous Friday. The study evaluated data from 96,000 infected patients from six continents including over 14,000 patients who had received chloroquine or hydroxychloroquine.

The outcomes demonstrated that the drugs augmented the risk of dying by over 35% and also doubled the risk of heart problems. Researchers were unable to approve the benefits of chloroquine or hydroxychloroquine for the treatment of COVID-19. The usage of these drugs for COVID-19 results in decreased in-hospital survival and an increased frequency of ventricular arrhythmias.

According to sources, the agency has implemented a provisional pause on the hydroxychloroquine wing of its Solidarity Trial. It is an international trial assessing the efficacy and safety of numerous drugs against COVID-19. The clinical trial has involved more than 400 hospitals in over 35 countries with 3500 patients.

The executive group of the clinical trial will review the data to assess the pros and cons of hydroxychloroquine drugs. Other arms of the clinical trial will continue to operate for assessing the safety and efficiency of numerous drugs.

WHO General Director, Tedros Adhanom Ghebreyesus said that the agency will provide further updates on the drug in the coming time.

In April, the US FDA also granted a caution against the use of chloroquine or hydroxychloroquine for COVID-19 outside of clinical trial or hospitals due to the risk of heart rhythm issues.

Source Credit - https://www.webmd.com/lung/news/20200527/who-pauses-hydroxychloroquine-clinical-trial

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...